{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:03:50Z","timestamp":1789473830064,"version":"build-2803163510"},"reference-count":73,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Program for Basic Research in the Russian Federation for a long-term period (2021\u20132030)","award":["124050800018-9"],"award-info":[{"award-number":["124050800018-9"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>RNA-based drugs hold significant potential, offering promising new treatments for a wide range of diseases, especially those with a genetic basis. By leveraging RNA interference (RNAi) and other RNA-mediated mechanisms, these therapies can precisely modulate gene expression and address the root causes of genetic defects. RNA-based drugs hold significant potential for treating a range of diseases. However, the transition of these therapies from laboratory research to clinical applications has encountered hurdles. This review explores the composition and outcomes of clinical trials for various modified short RNA drugs. We detail their mechanisms of action, delivery systems\u2014with a focus on lipid nanoparticles and N-acetylgalactosamine (GalNAc) conjugates\u2014and clinical efficacy in treating conditions such as transthyretin (TTR) amyloidosis. Our analysis reveals that while several RNAi-based drugs have achieved clinical approval, a critical unmet need remains: advanced delivery systems capable of precisely targeting diverse tissues, particularly outside the liver. We also underscore the importance of rigorous target validation utilising sophisticated bioinformatics tools and in vitro\/in vivo assays to minimise off-target effects and ensure robust therapeutic efficacy. This review proposes a novel framework for optimising RNA drug development, emphasising the crucial interplay between delivery strategies, target specificity, and understanding disease-specific target biology.<\/jats:p>","DOI":"10.3390\/ijms26178651","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:18:18Z","timestamp":1757074698000},"page":"8651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["siRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review"],"prefix":"10.3390","volume":"26","author":[{"given":"Alexei","family":"Shevelev","sequence":"first","affiliation":[{"name":"Laboratory of DNA metylom and transcriptom editing, Vavilov Institute of General Genetics of Russian Academy of Sciences, Gubkina 3, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-3016","authenticated-orcid":false,"given":"Natalia","family":"Pozdniakova","sequence":"additional","affiliation":[{"name":"Laboratory of radionuclide and radiation technologies in experimental oncology, Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Kashirskoe Shosse 24, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-6405","authenticated-orcid":false,"given":"Evgenii","family":"Generalov","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-7832","authenticated-orcid":false,"given":"Olga","family":"Tarasova","sequence":"additional","affiliation":[{"name":"Laboratory of Big Data Analysis for Digital Pharmacology, Department of Bioinformatics, Institute of Biomedical Chemistry of Russian Academy of Sciences, Pogodinskaya 10, 8, 119121 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Palmieri, L., Ferrand, M., Vu Hong, A., Richard, I., and Albini, S. (2024). In Silico Structural Prediction for the Generation of Novel Performant Midi-Dystrophins Based on Intein-Mediated Dual AAV Approach. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202409.0395.v1"},{"key":"ref_2","first-page":"e2402166","article-title":"AAV-Mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.ymthe.2024.07.026","article-title":"Full-Length Dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"32","author":"Duan","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhu, H., Zhu, S., Jiang, Q., Pang, Y., Huang, Y., Chen, Y., Hou, T., Deng, W., Liu, X., and Zeng, L. (2023). Vulto-van Silfhout-de Vries Syndrome Caused by de Novo Variants of DEAF1 Gene: A Case Report and Literature Review. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1251467"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, M.M., Bahal, R., Rasmussen, T.P., Manautou, J.E., and Zhong, X. (2021). The Growth of siRNA-Based Therapeutics: Updated Clinical Studies. Biochem. Pharmacol., 189.","DOI":"10.1016\/j.bcp.2021.114432"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients with Hereditary Transthyretin-Mediated Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical Evaluation of RNAi as a Treatment for Transthyretin-mediated Amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/nar\/gkz140","article-title":"Safety Evaluation of 2\u2032-Deoxy-2\u2032-Fluoro Nucleotides in GalNAc-siRNA Conjugates","volume":"47","author":"Janas","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","article-title":"Vutrisiran: A New Drug in the Treatment Landscape of Hereditary Transthyretin Amyloid Polyneuropathy","volume":"19","author":"Perrain","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine\u2013Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (2005). Acute Intermittent Porphyria. GeneReviews\u00ae, University of Washington."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute Hepatic Porphyrias: Current Diagnosis & Management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/metabo4040977","article-title":"Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias","volume":"4","author":"Besur","year":"2014","journal-title":"Metabolites"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and Kidney Diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMe2010986","article-title":"Givosiran\u2014Running RNA Interference to Fight Porphyria Attacks","volume":"382","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00240-018-1089-z","article-title":"Molecular Basis of Primary Hyperoxaluria: Clues to Innovative Treatments","volume":"47","author":"Dindo","year":"2019","journal-title":"Urolithiasis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/acs.bioconjchem.0c00268","article-title":"Investigational Therapies for Primary Hyperoxaluria","volume":"31","author":"Kletzmayr","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in Primary Hyperoxaluria Subtype 3: Results from a Phase I, Single-Dose Study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the Art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran-New Hope in the Management of Lipid Disorders?","volume":"14","author":"Penson","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide Therapeutics\u2014A New Class of Cholesterol-Lowering Drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","article-title":"Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin\/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study","volume":"141","author":"Hovingh","year":"2020","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41587-019-0351-4","article-title":"PCSK9-Gene-Silencing, Cholesterol-Lowering Drug Impresses","volume":"37","author":"Sheridan","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"m1159","DOI":"10.1136\/bmj.m1159","article-title":"Do PCSK9 Inhibitors Do Anything More than Reduce LDL Cholesterol?","volume":"368","author":"Bamji","year":"2020","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: Molecular and Clinical Similarities and Differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Hemophilia A and B Based on the Grading of Recommendations Assessment, Development, and Evaluation Methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/nat.2020.0852","article-title":"Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo","volume":"31","author":"Berk","year":"2021","journal-title":"Nucleic Acid Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current Prospects for RNA Interference-Based Therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_37","first-page":"85","article-title":"Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1681\/ASN.2008111204","article-title":"siRNA Targeted to P53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury","volume":"20","author":"Molitoris","year":"2009","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","article-title":"Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study","volume":"144","author":"Thielmann","year":"2021","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/ICU.0000000000000318","article-title":"The Enigma of Nonarteritic Anterior Ischemic Optic Neuropathy: An Update for the Comprehensive Ophthalmologist","volume":"27","author":"Gaier","year":"2016","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/cddis.2011.54","article-title":"Ocular Neuroprotection by siRNA Targeting Caspase-2","volume":"2","author":"Ahmed","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/nat.2014.0489","article-title":"Toxicological and Pharmacokinetic Properties of QPI-1007, a Chemically Modified Synthetic siRNA Targeting Caspase 2 mRNA, Following Intravitreal Injection","volume":"24","author":"Solano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/fcp.12561","article-title":"Progress on Ocular siRNA Gene-Silencing Therapy and Drug Delivery Systems","volume":"35","author":"Jiang","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a Novel siRNA for the Treatment of Dry Eye Disease","volume":"27","author":"Bleau","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1167\/iovs.18-24304","article-title":"TRPV1 and TRPM8 Channels and Nocifensive Behavior in a Rat Model for Dry Eye","volume":"59","author":"Bereiter","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jha2.748","article-title":"Results of a Phase 1\/2 Study of Cemdisiran in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"4","author":"Gaya","year":"2023","journal-title":"EJHaem"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A Synthetic microRNA-92a Inhibitor (MRG-110) Accelerates Angiogenesis and Wound Healing in Diabetic and Nondiabetic Wounds","volume":"26","author":"Piper","year":"2018","journal-title":"Wound Repair Regen."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bansal, R., Prakash, J., De Ruiter, M., and Poelstra, K. (2014). Targeted Recombinant Fusion Proteins of IFN\u03b3 and Mimetic IFN\u03b3 with PDGF\u03b2R Bicyclic Peptide Inhibits Liver Fibrogenesis In Vivo. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089878"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., and Saini, G. (2022). A Lung Targeted miR-29 Mimic as a Therapy for Pulmonary Fibrosis. eBioMedicine, 85.","DOI":"10.1016\/j.ebiom.2022.104304"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 Oligonucleotides Prevent Alport Nephropathy Progression by Stimulating Metabolic Pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-019-04241-7","article-title":"The Importance of Clinician, Patient and Researcher Collaborations in Alport Syndrome","volume":"35","author":"Rheault","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.12688\/f1000research.9636.1","article-title":"Alport Syndrome: Facts and Opinions","volume":"6","author":"Kashtan","year":"2017","journal-title":"F1000Research"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0300985818806050","article-title":"Abnormal Expression of miR-21 in Kidney Tissue of Dogs With X-Linked Hereditary Nephropathy: A Canine Model of Chronic Kidney Disease","volume":"56","author":"Clark","year":"2019","journal-title":"Vet. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Rubel, D., Boulanger, J., Craciun, F., Xu, E.Y., Zhang, Y., Phillips, L., Callahan, M., Weber, W., Song, W., and Ngai, N. (2022). Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models. Cells, 11.","DOI":"10.3390\/cells11040594"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","article-title":"A Randomized Controlled Clinical Trial Testing Effects of Lademirsen on Kidney Function Decline in Adults with Alport Syndrome","volume":"19","author":"Gale","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2215\/CJN.0000000000000506","article-title":"Lessons Learned from HERA: The First Alport Syndrome Therapeutic Clinical Trial","volume":"19","author":"Weinstock","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1172\/JCI127125","article-title":"Suppressing miR-21 Activity in Tumor-Associated Macrophages Promotes an Antitumor Immune Response","volume":"129","author":"Sahraei","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_58","first-page":"1834","article-title":"Regulatory Mechanism of MiR-21 in Formation and Rupture of Intracranial Aneurysm through JNK Signaling Pathway-Mediated Inflammatory Response","volume":"13","author":"Chen","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"107487","DOI":"10.1016\/j.phrs.2024.107487","article-title":"Global and Chinese Trends in Oligonucleotide Drug Clinical Development: A Comparative Analysis","volume":"210","author":"Wu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1073\/pnas.0601309103","article-title":"Determinants of Specific RNA Interference-Mediated Silencing of Human Beta-Globin Alleles Differing by a Single Nucleotide Polymorphism","volume":"103","author":"Dykxhoorn","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ahmed, F., and Raghava, G.P.S. (2011). Designing of Highly Effective Complementary and Mismatch siRNAs for Silencing a Gene. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023443"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1073\/pnas.81.2.466","article-title":"Rapid Release of Galactose-Terminated Ligands after Endocytosis by Hepatic Parenchymal Cells: Evidence for a Role of Carbohydrate Structure in the Release of Internalized Ligand from Receptor","volume":"81","author":"Townsend","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eabb8133","DOI":"10.1126\/sciadv.abb8133","article-title":"Transient Stealth Coating of Liver Sinusoidal Wall by Anchoring Two-Armed PEG for Retargeting Nanomedicines","volume":"6","author":"Dirisala","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ge, P., Dong, C., Ren, X., Weiderpass, E., Zhang, C., Fan, H., Zhang, J., Zhang, Y., and Xi, J. (2015). The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144104"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR\u2013Cas Gene Editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 Antisense Oligonucleotide AZD9150 in a Subset of Patients with Heavily Pretreated Lymphoma: Results of a Phase 1b Trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ymthe.2021.01.020","article-title":"A Versatile Platform for Generating Engineered Extracellular Vesicles with Defined Therapeutic Properties","volume":"29","author":"Dooley","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10265-016-0878-0","article-title":"Biogenesis of Diverse Plant phasiRNAs Involves an miRNA-Trigger and Dicer-Processing","volume":"130","author":"Komiya","year":"2017","journal-title":"J. Plant Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Verlaan, M.G., Hutton, S.F., Ibrahem, R.M., Kormelink, R., Visser, R.G.F., Scott, J.W., Edwards, J.D., and Bai, Y. (2013). The Tomato Yellow Leaf Curl Virus Resistance Genes Ty-1 and Ty-3 Are Allelic and Code for DFDGD-Class RNA\u2013Dependent RNA Polymerases. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003399"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1073\/pnas.0904086107","article-title":"RNAi-Mediated Viral Immunity Requires Amplification of Virus-Derived siRNAs in Arabidopsis Thaliana","volume":"107","author":"Wang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic Programming of Macrophages to Perform Anti-Tumor Functions Using Targeted mRNA Nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(Beta-Amino Ester)s as Gene Delivery Vehicles: Challenges and Opportunities","volume":"17","author":"Karlsson","year":"2020","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:40:08Z","timestamp":1760035208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":73,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178651"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178651","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}